Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Kinetics of [18F]-JNJ-70099731 in Healthy Males
NCT04911543Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-70099731 (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Normalized Cumulative Activity and Residence Time at Day 1, Radiation Absorbed Doses for 25 Organs and the Effective Dose (ED) at Day 1 and 2 more. Started Jun 2021; status: completed.
02
Drugs
JNJ-70099731
Beyond the preview
Go deeper on NCT04911543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911543.